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Contamination Identified in Additional Medical Products from 
New England Compounding Center
Summary: As part of the ongoing investigation of the multistate outbreak of fungal meningitis and other 
infections, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration 
(FDA) continue to test medical products from the New England Compounding Center (NECC) in 
Framingham, Mass. NECC is the firm that distributed and recalled injectable steroid medications 
implicated in the current outbreak of fungal meningitis and other infections. CDC and FDA are reporting 
today that product testing has identified bacterial contamination with several Bacillus species and closely 
related bacterial organisms in unopened vials of betamethasone and cardioplegia solution that were 
distributed and later recalled by NECC on October 6, 2012. These bacteria are commonly found in the 
environment and have been rarely reported as a cause of human disease; it is not known how product 
contamination with these species might affect patients. Although clinical infection is possible, CDC has 
not received reports of laboratory-confirmed cases of infection due to Bacillus or closely related 
organisms linked to these products. CDC’s recommendations to healthcare providers for diagnosing and 
treating symptomatic patients who have received NECC products have not changed as a result of these 
findings. Additional microbial organisms may be identified in recalled NECC products as additional 
laboratory testing is completed.
Background
On September 26, 2012, NECC voluntarily recalled three lots of methylprednisolone acetate (PF) 
80mg/ml1 associated with the multistate outbreak of fungal meningitis and other infections. As previously 
confirmed by CDC and FDA, the fungus Exserohilum rostratum was identified from two different lots of 
NECC-supplied, preservative-free methylprednisolone acetate (Lot #06292012@26 and Lot 
#08102012@51); testing on the third implicated lot of preservative-free methylprednisolone acetate (Lot 
#05212012@68) is ongoing. Two types of fungus not known to be human pathogens were also identified 
from product from the two tested lots, namely Rhodotorula laryngis and Rhizopus stolonifer. Among these 
fungal organisms, only Exserohilum rostratum has been associated with human infections in this 
outbreak.
On October 6, NECC expanded its recall to include all products in circulation that were distributed from its 
facility in Framingham, Mass. FDA released a MedWatch Safety Alert on October 15 stating that the 
sterility of any injectable drugs, including ophthalmic drugs that are injectable or used in conjunction with 
eye surgery, and cardioplegic solutions produced by NECC is of significant concern. As part of the 
ongoing investigation, FDA and CDC have been testing various NECC products for evidence of 
contamination. Laboratory testing at CDC and FDA has found multiple species of Bacillus and closely 
related bacterial organisms in unopened vials of betamethasone and cardioplegia solution, as shown in 
the table below.
Medication Lot number Microbial contamination
Betamethasone 08202012@141
Paenibacillus pabuli/amolyticus, Bacillus idriensis, 
Bacillus flexus, Bacillus simplex, Lysinibacillus sp.
Betamethasone 07032012@22
Bacillus niabensis, Bacillus circulans
Betamethasone 07302012@52 Bacillus lentus, Bacillus circulans
Cardioplegia solution 09242012@55 Bacillus halmapalus, Brevibacillus choshinensis
Other cultures for these products, including fungal cultures, are pending.
Recommendations to Healthcare Providers
CDC and FDA have previously advised that healthcare professionals should cease use of any product 
produced by NECC. On October 15, FDA issued a MedWatch Safety Alert advising clinicians to follow-up 
with patients who received any injectable NECC product, including betamethasone or cardioplegia 
solution purchased from or distributed by NECC after May 21, 2012. Clinicians were also requested to 
report any suspected adverse events following use of these products to FDA's MedWatch program.
CDC continues to investigate reports of potential infections in patients receiving other NECC 
products. As of November 1, CDC has received no reports of confirmed infections resulting from injection
of any NECC product except those from the three recalled lots of preservative-free methylprednisolone
[1 ]
acetate.
CDC’s recommendations to healthcare providers for diagnosing and treating symptomatic patients who 
have received NECC products have not changed as a result of these findings. CDC continues to 
recommend routine laboratory and microbiologic tests, including bacterial and fungal cultures, deemed 
necessary by treating clinicians.
These bacteria have been rarely reported as a cause of human disease. Nevertheless, clinicians should 
consider these product findings when reviewing laboratory results from patients who have been exposed 
to a NECC product, since Bacillus and related bacteria are often considered in clinical results to be 
possible skin contaminants. Physicians should continue to report infections potentially related to NECC 
products to FDA ’s MedWatch and to state health departments.
[1] NECC lots of methylprednisolone acetate (PF) 80mg/ml:
Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68, BUD 11/17/2012 
Methylprednisolone Acetate (p f ) 80 mg/ml Injection, Lot #06292012@26, BUD 12/26/2012 
Methylprednisolone Acetate (p f ) 80 mg/ml Injection, Lot #08102012@51, BUD 2/6/2013
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
international organizations.
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